Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy

Blum, David; Meador, Kimford J.; Biton, Victor; Fakhoury, Toufic; Shneker, Bassel F.; Chung, Suk Jae; Mills, Kenneth C.; Hammer, Anne E.; Isojärvi, Jouko

doi:10.1212/01.wnl.0000232737.72555.06

Cited by 110 publications

(72 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Comparison of LTG to non-drug average revealed better performance on seven (17%) variables for non-drug average and four (10%) variables for LTG. Similar differences between lamotrigine (mean dose = 500 mg/day) and topiramate (mean dose = 300 mg/day) were seen in a multi-center, double-blind, randomized, prospective study of adults with partial seizures who were treated with lamotrigine or topiramate as adjunctive therapy to carbamazepine or phenytoin (Blum et al 2006). …”

Section: Topiramate (Topamax)mentioning

confidence: 59%

Neuropsychological and Behavioral Effects of Antiepilepsy Drugs

2007

View full text Add to dashboard Cite

Antiepilepsy drugs work by decreasing neuronal irritability, which may also result in the non-desired side effect of decreased neuropsychological function. In addition to cognitive side effects, antiepilepsy drugs (AEDs) may be associated with behavioral effects which may range from irritability and hyperactivity to positive psychotropic effects on mood. There have been many new medications released since the 1990s, and although they tend to have more favorable side effect profiles compared to their older counterparts, there continues to be a risk of decreased cognitive function with the majority of these agents. The effects of in utero antiepilepsy drug exposure are increasingly being investigated, and differential drug risk is beginning to be described for both anatomic and cognitive outcomes. Patients with epilepsy undergoing neuropsychological evaluations are commonly on AEDs, and it is important for the clinician to recognize the potential contribution of AED therapy to neuropsychological profiles. The present article serves to provide an overview of our current understanding regarding the risks of antiepilepsy drug use for both cognitive and behavioral side effects.

show abstract

Section: Topiramate (Topamax)mentioning

confidence: 59%

Neuropsychological and Behavioral Effects of Antiepilepsy Drugs

2007

View full text Add to dashboard Cite

show abstract

“…Unexpected side effects were not observed here. [23][24][25] The frequency of the side effects decreased after the first month, but weight loss increased.…”

Section: Discussionmentioning

confidence: 99%

Effects of topiramate on neurophysiological and neuropsychological tests in migraine patients

Kececi¹,

Atakay²

2009

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

“…We have compared our results to published results of the minimum clinically important difference (MCID) [42]. This is defined as the smallest difference in result which can be perceived by the patient and is therefore clinically relevant.…”

Section: Discussionmentioning

confidence: 99%

No improvement in neurocognitive outcomes after off-pump versus on-pump coronary revascularisation: a meta-analysis

Marasco

Sharwood

Abramson

2008

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

The popularity of off-pump (beating heart) coronary artery bypass grafting (CABG) was initially stimulated by numerous theoretical benefits including lower incidence of stroke and neurocognitive dysfunction. With a postoperative stroke rate of less than 1% for elective CABG, it has been very difficult to demonstrate any significant differences in this outcome between techniques. However, changes in neurocognitive function are more common in the postoperative setting and thus provide greater power for demonstrating improvement with changes in surgical technique. The aim of this meta-analysis was to assess whether there were significant differences in neurocognitive outcomes in patients after undergoing off-pump versus on-pump CABG. A database search for prospective randomised controlled trials of off-pump versus on-pump CABG in any language was conducted. Eight trials incorporating 892 patients fulfilled all the inclusion criteria for reporting of neurocognitive outcomes, and were able to be included in this meta-analysis. Sufficient data were available across the seven studies to combine results for five neurocognitive tests (Rey Auditory Verbal Learning, Grooved Pegboard, Trail A and B, and Digit Symbol). Overall there were no convincing differences in outcomes in neurocognitive testing between off-pump and on-pump CABG groups. The results of this meta-analysis show that there are no significant neurocognitive benefits when comparing off-pump versus on-pump CABG.

show abstract

Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy

Abstract: Lamotrigine had significantly less impact than topiramate on measures of cognition when used as adjunctive therapy for partial seizures.

Cited by 110 publications

References 27 publications

Neuropsychological and Behavioral Effects of Antiepilepsy Drugs

Neuropsychological and Behavioral Effects of Antiepilepsy Drugs

Effects of topiramate on neurophysiological and neuropsychological tests in migraine patients

No improvement in neurocognitive outcomes after off-pump versus on-pump coronary revascularisation: a meta-analysis

Contact Info

Product

Resources

About